Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary therapy of advanced follicular lymphoma with immunochemotherapy induction followed by rituximab maintenance versus observation
2005-005473-29Phase 3Completed
- Sponsor
- LMU Klinikum
- Start
- Sep 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL) (5 arms), sponsored by LMU Klinikum. Primary endpoint: Complete remission rate after induction. Started Sep 2006; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2005-005473-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005473-29.